Glaukos Q2 net sales up 11% to $80.4M; raises FY2023 revenue guidance

GLAUKOS Corp

2023-Q2 EPS reported -$1.40 revenue$154,298,000

Q2 net sales $80.4M, +11% YoY; glaucoma sales $61.9M (+10%), corneal health $18.5M (+11% YoY).
GAAP net loss per diluted share ($0.68) vs ($0.96) in Q2 2022; non-GAAP loss per share ($0.55) vs ($0.83).
Gross margin ~75%; non-GAAP gross margin ~82%; cash and investments $310M at quarter-end.
2023 net sales guidance raised to $304-308M from $295-300M previously.
Operating loss narrowed to $29.1M from $36.8M; SG&A +6% to $53.1M, R&D +5% to $33.2M.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

GLAUKOS Corp reported 2023 results: revenue $304 million to $308 million. Guidance raised.

Period: 2023
Revenue: $304 million to $308 million
Guidance: raised
Result: guidance update

Exact text from the filing

Raised 2023 net sales guidance to $304 million to $308 million, compared to $295 million to $300 million previously.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

GLAUKOS Corp reported the second quarter ended June 30, 2023 results: revenue $80.4 million, net income $32.8 million, EPS ($0.68) per diluted share.

Period: the second quarter ended June 30, 2023
Revenue: $80.4 million
Net income: $32.8 million
EPS: ($0.68) per diluted share
Result: reported results

Exact text from the filing

Net sales in the second quarter of 2023 of $80.4 million increased 11%, compared to $72.7 million in the same period in 2022. Gross margin for the second quarter of 2023 was approximately 75%, compared to approximately 75% in the same period in 2022. Non-GAAP gross margin for the second quarter of 2023 was approximately 82%, compared to approximately 83% in the same period in 2022. Selling, general and administrative (SG&A) expenses for the second quarter of 2023 increased 6% to $53.1 million, compared to $49.9 million in the same period in 2022. Non-GAAP SG&A expenses for the second quarter of 2023 increased 7% to $52.4 million, compared to $49.0 million in the same period in 2022. GAAP and non-GAAP research and development (R&D) expenses for the second quarter of 2023 increased 5% to $33.2 million, compared to $31.7 million in the same period in 2022. 1 Loss from operations in the second quarter of 2023 was $29.1 million, compared to operating loss of $36.8 million in the second

View on SEC.gov

Browse all earnings releases →

GLAUKOS Corp filing history →

Source: SEC EDGAR

accession 0001558370-23-012911

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.